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Lymphangioleiomyomatosis (LAM) is a female-predominant interstitial lung disease that can lead to respiratory failure. LAM
cells typically have inactivating TSC2 mutations, leading to mTORC1 activation. The gender speciﬁcity of LAM suggests that
estradiol contributes to disease development, yet the underlying pathogenic mechanisms are not completely understood. Using
metabolomic proﬁling, we identiﬁed an estradiol-enhanced pentose phosphate pathway signature in Tsc2-deﬁcient cells.
Estradiol increased levels of cellular NADPH, decreased levels of reactive oxygen species, and enhanced cell survival under
oxidative stress. Mechanistically, estradiol reactivated Akt in TSC2-deﬁcient cells in vitro and in vivo, induced membrane
translocation of glucose transporters (GLUT1 or GLUT4), and increased glucose uptake in an Akt-dependent manner.
18F-FDG-
PET imaging demonstrated enhanced glucose uptake in xenograft tumors of Tsc2-deﬁcient cells from estradiol-treated mice.
Expression array study identiﬁed estradiol-enhanced transcript levels of glucose-6-phosphate dehydrogenase (G6PD), the rate-
limiting enzyme of the pentose phosphate pathway. Consistent with this, G6PD was abundant in xenograft tumors and lung
metastatic lesions of Tsc2-deﬁcient cells from estradiol-treated mice. Molecular depletion of G6PD attenuated estradiol-
enhanced survival in vitro, and treatment with 6-aminonicotinamide, a competitive inhibitor of G6PD, reduced lung colonization
of Tsc2-deﬁcient cells. Collectively, these data indicate that estradiol promotes glucose metabolism in mTORC1 hyperactive
cellsthroughthe pentose phosphate pathway via Aktreactivation and G6PD upregulation, thereby enhancingcell survivalunder
oxidative stress. Interestingly, a strong correlation between estrogen exposure and G6PD was also found in breast cancer cells.
Targeting the pentose phosphate pathway may have therapeutic beneﬁt for LAM and possibly other hormonally dependent
neoplasms.
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Lymphangioleiomyomatosis (LAM), a rare cystic lung disease
with multi-organ involvement, occurs primarily in women of
childbearing age.
1–3 LAM is characterized pathologically by
widespreadproliferationofabnormalsmoothmusclecellsand
by cystic changes within the lung parenchyma.
1–3 About 60%
of women with the sporadic form of LAM also have renal
angiomyolipomas. The presence of TSC2 mutations in LAM
cells and renal angiomyolipoma cells from women with
sporadic LAM, but not in normal tissues, has led to the
hypothesis that LAM cells spread to the lungs via a metastatic
mechanism,
4 despite the fact that LAM cells have a
histologically benign appearance. Genetic and ﬂuorescent
in situ hybridization analyses of recurrent LAM after lung
transplantation support this benign metastatic model.
4,5
Alterations in cellular energy metabolism are a hallmark of
cancer.
6 Many cancer cells generate the majority of their ATP
by converting glucose to lactate, a process that was ﬁrst
recognized in 1930 and is referred to as the Warburg effect.
7
There are several indications that cells carrying mutations in
the TSC genes have defects in energy metabolism. Cells
lacking TSC2 undergo massive apoptosis in glucose-free
growth conditions.
8 Rapamycin reduces lactate production
but does not affect cellular ATP levels in Tsc2
 /  MEF cells.
9
Cells lacking Tsc1 or Tsc2 have increased expression of
genes encoding the enzymes of lipid and sterol biosynthesis,
glycolysis, and the pentose phosphate pathway.
10 Cells with
mTOR hyperactivation exhibit PKM2-stimulated glycolysis.
11
Pentose phosphate pathway is a critical autophagy-depen-
dent compensatory metabolic reprogramming in Tsc2-deﬁ-
cient cells.
12 Despite these ﬁndings, the role of estradiol in
regulating cellular metabolism in Tsc2-deﬁcient cells has not
been extensively investigated.
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www.nature.com/cddisThe female predominance of LAM, coupled with the genetic
data indicating that LAM cells are metastatic, suggests that
estradiol may promote the metastasis of Tsc2-deﬁcient cells.
Both LAM cells and angiomyolipoma cells express estradiol
receptor alpha and progesterone receptor, and the symptoms
of LAM can worsen during pregnancy.
1–3 Although we have
previously found that estradiol promotes the survival and
metastasis of Tsc2-deﬁcient cells, the molecular and cellular
mechanisms that may underlie this are not completely
understood.
We report here that estradiol treatment of TSC2-deﬁcient
cells is associated with elevated levels of pentose phosphate
pathway intermediates, Akt-dependent membrane transloca-
tion of the glucose transporters (GLUT1 or GLUT4), and
enhanced glucose uptake in vitro and in vivo. 6-amino-
nicotinamide (6-AN), a competitive inhibitor of the pentose
phosphate pathway,
13 suppressed estradiol-induced cell
survival in vitro and in vivo. Taken together, these data reveal
that pentose phosphate pathway is a critical component of the
estradiol-dependent cell survival of TSC2-deﬁcient cells, and
point toward novel therapeutic targets for LAM and potentially
for other hormonally dependent neoplasms associated with
mTORC1 activation.
Results
Identiﬁcation of estradiol-induced metabolic signature
of the pentose phosphate pathway in Tsc2-deﬁcient
cells. To elucidate pro-survival events mediated by estradiol
(E2) in Tsc2-deﬁcient rat uterus-derived ELT3 cells,
14,15
we performed a metabolomics screen by LC/MS/MS.
A signiﬁcant increase in glycolysis and pentose phosphate
pathway intermediates (Figure 1a), including glucose (3.6-
fold), glucose-6-phosphate (2.6-fold), fructose-6-phosphate
(2.5-fold), ribose (3.6-fold), ribose-5-phosphate (2.2-fold),
and ribulose-5-phosphate (2.2-fold), were observed in
E2-stimulated cells at 24h (Figure 1b). Furthermore, E2
increased the cellular levels of NADPH (Figure 1c) and
decreased the levels of reactive oxygen species (ROS)
(Figure 1d) in the presence or absence of hydrogen peroxide
(H2O2) at 24h. However, E2 did not affect the secretion of
lactate, the end product of glycolysis (Figure 1e).
To determine the effect of E2 in the survival of TSC2-
deﬁcient cells under oxidative stress, cells were treated with
H2O2 or vehicle for 0.5h in the presence or absence of E2 for
additional 24h. H2O2-triggered cell death was strongly
rescued by E2 stimulation by 26% (Po0.01) in comparison
with vehicle control in LAM patient-derived cells (Figures
1f and g). Using the PI exclusion assay, E2 signiﬁcantly
reduced H2O2-induced cell death by50% (Po0.01) relative to
control in rat-derived cells (Figures 1h and i). These data
suggest that E2 enhances the survival of ELT3 cells
particularly under conditions of oxidative stress. Collectively,
these data indicate that E2 promotes pentose phosphate
pathway addiction in cells lacking TSC2 (Figure 1j).
Estradiol reactivates Akt in TSC2-deﬁcient cells in vitro
and in vivo. To deﬁne signaling events that potentially
mediate E2-enhanced glucose metabolism, we examined the
activation of Akt and ERK1/2, which are known signaling
molecules inﬂuenced by E2. Under basal conditions, levels of
phospho-Akt S473 were lower in TSC2-deﬁcient LAM
patient-derived cells relative to TSC2-addback cells
(Figure 2a), as expected. Interestingly, E2 strongly reacti-
vates Akt (S473) at 1h and sustains Akt activation to 24h
in TSC2-deﬁcient LAM patient-derived cells (TSC2 )
(Figure 2b). We also found that E2 activates ERK1/2
(T202/Y204), as expected. In contrast, E2 modestly stimu-
lates Akt at 1h to 8h in TSC2-re-expressing cells (TSC2þ)
(Figure 2c). Notably, E2 did not further enhance phosphor-
ylation of ribosomal protein S6 (S6) (S235/236) (Figures 2b
and c). Next, we examined Akt activation in Tsc2-deﬁcient
ELT3 cells, and found that E2 stimulation resulted in a
biphasic activation of Akt at 15–30min and 6h in vitro
(Figure 2d). E2 also induced a biphasic activation of ERK1/2,
as previously reported.
16–18
To assess the effect of E2 in Akt activation in vivo,w e
subcutaneously inoculated ELT3 cells into ovariectomized
female SCID mice supplemented with E2 or placebo. E2
treatment led to a 2.3-fold increase of tumor volume at
8 weeks post cell inoculation (Figure 2e). Immunoblotting
analysis showed that xenograft tumors from E2-treated mice
have higher levels of phospho-Akt (S473) and phospho-ERK
(T202/Y204) compared with placebo treatment (Figure 2f).
Moreover, immunohistochemical staining showed that
xenograft tumors from E2-treated mice exhibit higher levels
of phospho-Akt (Ser473) relative to the placebo treatment
(Figure 2g). Because Tsc2-deﬁcient cells exhibit low Akt
Figure 1 Identiﬁcation of estradiol-induced metabolic signature of pentose phosphate pathway in Tsc2-deﬁcient cells in vitro.( a) ELT3 (Tsc2-deﬁcient rat uterus-derived) cells
were treated with estradiol (10nM) for 2 and 24h. Cellular metabolites were proﬁled by mass spectrometry (n¼5) (Metabolon LC-MS/MS). (b) Box-plots of glucose, glucose-6-
phosphate, fructose-6-phophate, ribose, ribose-5-phosphate, and ribulose-5-phosphate are shown. Data show the mean of ﬁve sets of independent samples. (c) Cellular NADPH
levelsweremeasuredinrat-derivedTsc2-deﬁcientcellstreatedwithcontrolorestradiol(10nM)for2and24h.Datawerenormalizedtototalprotein level.Resultsarerepresentative
of three sets of independent samples per group from three experiments. (d) Cellular ROS levels were measured using DCFH-DA in rat-derived Tsc2-deﬁcient cells treated with
control or estradiol (10nM) for 24h. Cells were incubated with hydrogen peroxide (H2O2) (0.5mM) for 1h before measurement. Data were normalized to total cell number. Results
are representative of eight independent samples per group from three experiments. (e) Extracellular lactate levels were measured in rat-derived Tsc2-deﬁcient cells treated with
control or estradiol (10nM) for 24h. FBS (10%) stimulation was included as a positive control. Lactate levels were normalized to total proteins. Results are representative of three
sets of independent samples per group from three experiments. (f) Patient-derived TSC2-deﬁcient cells were treated with control or estradiol (10nM) for 24h, and then incubated
with hydrogen peroxide (0.5mM) for 0.5h. Cell morphology was recorded using phase-contrast microscopy. (g) Patient-derived TSC2-deﬁcient cells were treated with control or
estradiol (10nM) for 24h, and then incubated with H2O2 (0.5mM) for 0.5h. Cell death was measured using the propidium iodide (PI) exclusion assay. Proportion of dead cells was
normalizedtothetotalnumber ofvariablecells.Resultsarerepresentativeofeightindependent samplesper groupfromthreeexperiments.(h)Rat-derivedTsc2-deﬁcientcells were
treatedwithcontrolorestradiol(10nM)for24h,andthenincubatedwithhydrogenperoxide(0.5mM)for1h.Cellmorphologywasrecordedusingphase-contrastmicroscopy.
(i)Rat-derivedTsc2-deﬁcient cellsweretreatedwithcontrolorestradiol(10nM)for24h,andthenincubatedwithH2O2 (0.5mM)for1h.CelldeathwasmeasuredusingthePI
exclusion assay. Proportion of dead cells was normalized to the total number of variable cells. Results are representative of eight independent samples per group from three
experiments. (j) Scheme of glucose metabolism in TSC2-deﬁcient cells treated with estradiol. *Po0.05, **Po0.01
Estradiol enhances glucose utilization via Akt
Y Sun et al
2
Cell Death and DiseaseControl E2-2h E2-24h
Min Max
Glucose
R
e
l
a
t
i
v
e
 
l
e
v
e
l
R
e
l
a
t
i
v
e
 
l
e
v
e
l
R
e
l
a
t
i
v
e
 
l
e
v
e
l
R
e
l
a
t
i
v
e
 
l
e
v
e
l
R
e
l
a
t
i
v
e
 
l
e
v
e
l
R
e
l
a
t
i
v
e
 
l
e
v
e
l
Con E2
0.0
0.5
1.0
1.5 **
Glucose-6
-phosphate
Con E2
0.0
0.5
1.0
1.5 **
Con E2
0.0
0.5
1.0
1.5
Fructose-6
-phosphate
*
Ribose
Con E2
0.0
0.5
1.0
1.5
**
Ribose-5
-phosphate
Con E2
0.0
0.5
1.0
1.5 **
Riboluse-5
-phosphate
Con E2
0.0
0.5
1.0
1.5 **
N
A
D
P
H
 
n
g
/

g
 
p
r
o
t
e
i
n
2h 24h
0
20
40
60 Control
E2
*
R
O
S
 
r
e
l
a
t
i
v
e
 
l
e
v
e
l
Control E2 Control E2
0.0
0.5
1.0
1.5
2.0 **
**
**
H2O2
L
a
c
t
a
t
e
 
/
 
c
e
l
l
 
t
o
t
a
l
 
p
r
o
t
e
i
n
(
n
m
o
l
/

g
)
Control E2 FBS
0.0
0.1
0.2
0.3
0.4
N/S
V
e
h
i
c
l
e
H
2
O
2
Control E2
Control E2
V
e
h
i
c
l
e
H
2
O
2
C
e
l
l
 
d
e
a
t
h
 
%
Control E2 Control E2
0
10
20
30
**
**
H2O2
C
e
l
l
 
d
e
a
t
h
 
%
Control E2 Control E2
0
10
20
30
40
**
**
H2O2
Rat derived cells (TSC2-)
Rat derived cells (TSC2-) Rat derived cells (TSC2-) Rat derived cells (TSC2-)
Patient derived cells (TSC2-) Patient derived cells (TSC2-)
Rat derived cells (TSC2-) Rat derived cells (TSC2-)
Estradiol enhances glucose utilization via Akt
YS u net al
3
Cell Death and Diseaseactivation due to feedback inhibition mechanism,
19 these data
reveal that E2 reactivates Akt pathway in cells lacking TSC2.
Estradiol promotes plasma membrane translocation of
glucose transporters GLUT1 or GLUT4 and glucose
uptake in an Akt-dependent manner. Glucose entry into
cells is facilitated by proper localization of glucose transpor-
ters including GLUT1 and GLUT4.
20 To examine the impact
of E2 on GLUT1 and GLUT4 localization, TSC2-deﬁcient
LAM patient-derived or rat-derived cells were treated with E2
for 24h. Confocal microscopy showed that E2 promoted
plasma membrane translocation of GLUT4, but not GLUT1,
compared with control in LAM patient-derived cells
(Figure 3a). Interestingly, treatment of mTORC1 inhibitor
rapamycin led to plasma membrane translocation of GLUT4.
Importantly, E2-promoted membrane localization of GLUT4
was abolished by wortmannin treatment (Figure 3a).
Furthermore, Akt inhibitors MK2206 and wortmannin strongly
suppressed E2-induced phosphorylation of Akt (S473), but
not phosphorylation of ERK or S6, in patient-derived cells
(Figure 3b). Moreover, analysis of rat-derived Tsc2-deﬁcient
cells showed that rapamycin treatment led to plasma
membrane localization of GLUT1 (Figure 3c). Importantly,
E2 promoted membrane localization of GLUT1, which was
abolished by wortmannin treatment (Figure 3c). Immunoblot
analysis showed that wortmannin treatment markedly
decreased E2-induced phosphorylation of Akt (S473), but
not phosphorylation of S6 (Figure 3d). Together, these data
suggest that Akt speciﬁcally mediates the effect of E2 on
GLUT1 or GLUT4 trafﬁcking in TSC2-deﬁcient cells.
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Figure 2 EstradiolreactivatestheAktsignalingpathwayinvitroandinvivo.( a)Immunoblotanalysesof TSC2,phospho-Akt(Ser473),phospho-ERK1/2(Thr202/Tyr204),
phospho-S6 (Ser235/236), and b-actin in patient-derived TSC2-deﬁcient or TSC2-re-expressing cells treated with control or rapamycin for 12h. Results are representative of
three independent experiments. (b and c) Immunoblot analyses of TSC2, phospho-Akt (S473), phospho-ERK (Thr202/Tyr204), phospho-S6 (Ser235/236), and b-actin in
patient-derivedTSC2-deﬁcientorTSC2-re-expressingcellstreatedwithestradiol.Resultsarerepresentativeofthreedifferentexperiments.(d)ImmunoblotanalysesofTSC2,
phospho-Akt (S473), phospho-ERK (Thr202/Tyr204), phospho-S6 (Ser235/236), and b-actin in rat-derived Tsc2-deﬁcient cells treated with estradiol. Results are
representative of three differentexperiments. (e) ELT3 cells were subcutaneously injected into female ovariectomized miceimplanted with estradiol or placebopellets. Tumor
volume was calculated at week 8 post cell inoculation. (f) Immunoblot analyses of phospho-Akt (S473), phospho-ERK (Thr202/Tyr204), and b-actin in xenograft tumors from
mice treated with estradiol or placebo. (g) Immunohistochemistry of phospho-Akt (Ser473) in xenograft tumors of rat-derived Tsc2-deﬁcient cells from mice treated with
estradiol or placebo. Results are representative of ﬁve mice in each group. **Po0.01
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Figure 3 Estradiol enhances GLUT1 and GLUT4 plasma membrane translocation and glucose uptake via PI3K/Akt in TSC2-deﬁcient cells. (a) Patient-derived Tsc2-
deﬁcient cells were treated with rapamycin (10nM), wortmannin (500nM) for 15min, and then treated with control or estradiol (10nM) for 12h. Subcellular localization of
GLUT1 and GLUT4 was examined using confocal microscopy. (b) Patient-derived Tsc2-deﬁcient cells treated with estradiol (10nM) at 12h in the presence or absence of
MK2206 (2mM) or wortmannin (500nM) for 15min. Immunoblot analyses of phospho-Akt (Ser473), phospho-ERK1/2 (Thr202/Tyr204), phospho-S6 (Ser235/236), and
b-actin. Results are representative of three independent experiments. (c) Rat-derived Tsc2-deﬁcient cells were treated with rapamycin (10nM), or wortmannin (1mM) for
15min, and then treated with control or estradiol (10nM) for 24h. Subcellular localization of GLUT1 was examined using confocal microscopy. (d) Patient-derived
TSC2-deﬁcient cells treated with estradiol (10nM) at 12h in the presence or absence of wortmannin (500nM) for 15min. Immunoblot analyses of phospho-Akt (Ser473),
phospho-ERK1/2 (Thr202/Tyr204), phospho-S6 (Ser235/236), and b-actin. Results are representative of three independent experiments. (e) 2-NBDG uptake was measured
in patient-derived cells treated with control or estradiol. (f) Glucose uptake was measured by 2-NBDG ﬂuorescence in patient-derived TSC2-deﬁcient cells treated
with estradiol in the presence or absence of wortmannin (500nM) or rapamycin (10nM) for 15min before treatment. (g) Rat-derived Tsc2-deﬁcient cells were treated with
wortmannin (500nM) for 15min, and then treated with control or estradiol (10nM) for 24h. Extracellular glucose levels were measured in conditioned media. Data were
normalized to thecontrolgroup. (h) Representativeimagesof [
18F]FDG-PET/CTscanningof estradiolor placebo-treated micebearing xenografttumors of ELT3 cells.(i)The
graph indicates the average intensity at 40min of tumor FDG uptake. *Po0.05, **Po0.01
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Cell Death and DiseaseTodeterminetheimpactofE2onglucoseuptakeinvitro,we
ﬁrst assessed the direct glucose uptake using 2-NBDG
(2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose),
a ﬂuorescently labeled deoxyglucose analog. Confocal
microscopy showed that E2 treatment led to higher levels of
internalized 2-NBDG relative to vehicle treatment (Figure 3e).
Fluorescent quantiﬁcation showed that E2 treatment
increased 2-NBDG uptake by 60% (Po0.01) at 30min
compared with vehicle treatment (Figure 3f), and this was
signiﬁcantly decreased by wortmannin treatment (Po0.01),
but not affected by rapamycin treatment in patient-derived
cells (Figure 3f). We next examined the rate of glucose
consumption in conditioned media. E2 signiﬁcantly increased
glucose consumption by B10% (Po0.01) in comparison with
vehicle at 24h (Figure 3g), indicating that E2 enhanced
glucose uptake in rat-derived Tsc2-deﬁcient ELT3 cells.
Importantly, wortmannin treatment reduced the rate of
E2-enhanced glucose uptake (Figure 3g). Collectively, these
data demonstrate that Akt speciﬁcally mediates the effect of
E2 on glucose uptake in cells lacking TSC2 in vitro.
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Figure 4 G6PD expression is elevated in Tsc2-deﬁcient cells in vitro and in vivo.( a) Transcript levels of G6PD were measured using real-time RT-PCR in patient-derived
TSC2-deﬁcient cells treated with control or estradiol. (b) Immunoblot analyses of G6PD and b-actin in patient-derived TSC2-deﬁcient cells treated with estradiol.
A densitometry analysis of G6PD was performed. Results are representative of three different experiments. (c) Immunoblot analyses of phospho-Akt (Ser473), G6PD,
phospho-ERK1/2 (Thr202/Tyr204), phospho-S6(Ser235/236), and b-actin in patient-derived TSC2-deﬁcient cells treated with estradiol for 12h in the presence or absence of
MK2206 (2mM), wortmannin (500nM), AZD6244 (500nM), or PD98059 (50mM) for 15min before treatment. Results are representative of three different experiments.
(d) Immunoblot analyses of G6PD and b-actin in rat-derived Tsc2-deﬁcient cells treated with estradiol at the indicated time points. A densitometry analysis of G6PD was
performed. Results are representative of three different experiments. (e) Immunoblot analyses levels of G6PD and b-actin in xenograft tumors of ELT3 cells. A densitometry
analysis of G6PD was performed. Results are representative of three different experiments. (f) Immunohistochemistry of G6PD in xenograft tumors of ELT3 cells and lung
metastatic lesions from mice treated with estradiol or placebo. Results are representative of ﬁve mice in each group. *Po0.05, **Po0.01
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Cell Death and DiseaseTo determine whether E2 affects glucose uptake in vivo,E 2
orplacebo-treated mice bearing establishedxenograft tumors
of Tsc2-deﬁcient ELT3 cells were subjected to 2-[
18F]Fluoro-
2-deoxyglucose positron emission tomography/computed
tomography (FDG-PET/CT) imaging. The representative
images show the [
18F]FDG-PET/CT scanning of E2 or
placebo-treated mice bearing xenograft tumors of ELT3 cells
(Figure 3h). The FDG uptake in the tumors on the left for both
mice appeared to be similar. However, standardized uptake
value (SUV)max measured over the volume of the tumor
indicated a higher FDG uptake in E2 (SUVmax¼7.54 (right)
and 6.88 (left)) than in the control animal (SUVmax¼4.72
(right) and 3.74 (left)) (Figure 3i). The average tumor FDG
uptake increased by B50% in E2-treated mice relative to
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Figure 5 G6PDexpressionis estradiol-dependentin femalecancers.(a)Genomicalterations of G6pdweredeterminedinTCGA-curatedfemalecancersincludingovary,
uterine, cervix, and breast.
23 The colored boxes denote various alterations: green, mutation; dark blue, deletion; red, ampliﬁcation; gray, multiple alterations. (b–e) Levels of
G6pdmRNA weredeterminedusing cDNA microarray analyses of publicly availablemicroarray data sets.(b) Breastcancer MCF-7 cells were treatedwith estradiol or control
(GEO data set GDS3217). (c) MCF-7 cells were estradiol starved for 0, 1, or 2 days (GEO data set GDS2323). (d) MCF-7 cells were transfected with estrogen receptor a
(ERa)-siRNA (ERa silence) or control-siRNA (control) (GEO data set GDS4061). (e) MDA231 (ER-negative), ZR75 (ER-positive), and B6TC hybrid (estrogen-independent)
(GEO data set GDS4067). **Po0.01
Estradiol enhances glucose utilization via Akt
YS u net al
7
Cell Death and Diseaseplacebo-treated mice (P¼0.015, Figure 3i). These data
indicate that E2 enhances glucose uptake by Tsc2-deﬁcient
tumor cells in vivo.
Estradiol increases the expression of glucose-6-phos-
phate dehydrogenase in vitro and in vivo. To explore the
impact of E2 on the ﬂux of glucose to pentose phosphate
pathway at the mechanistic level in TSC2-deﬁcient cells, we
ﬁrst examined the transcript levels of glucose-6-phosphate
dehydrogenase (G6PD), the ﬁrst rate-limiting enzyme of the
pentose phosphate pathway. E2 treatment increased the
transcript levels of G6PD at 24h by Btwofold relative to
vehicle control in patient-derived cells (Po0.05, Figure 4a). It
has been reported that G6PD alternative splicing is one of
the regulatory mechanisms responsible for G6PD expres-
sion.
21,22 We performed real-time RT-PCR analysis using
primers speciﬁc to the pre-mRNA and mature mRNA of
G6PD. We found that estradiol treatment did not alter the
G6PD mature mRNA/pre-mRNA ratio in LAM patient-derived
cells (Supplementary Figure S1). Furthermore, cells stimu-
lated by E2 exhibited higher levels of G6PD protein by
Btwofold at 2–24h in patient-derived cells (Po0.01,
Figure 4b). Importantly, the estrogen receptor antagonist
ICI 182780 (Faslodex or Fulvestrant) strongly reduced E2-
increased G6PD protein in patient-derived cells (Figure 4c).
To examine whether Akt is a critical mediator of G6PD
expression, we treated patient-derived cells with MK-2206
(an allosteric Akt inhibitor), or wortmannin (an irreversible
PI3K inhibitor) for 24h. We found that both inhibitors
markedly reduced E2-increased G6PD protein (Figure 4c),
further supporting that Akt is a critical component in E2-
altered glucose metabolism in cells lacking TSC2. Interest-
ingly, MEK/1/2 inhibitors AZD6244 or PD98059 had modest
effect on E2-enhanced G6PD expression (Figure 4c). We
also found that E2 increased the levels of G6PD protein in
rat-derived cells within 24h (Figure 4d), consistent with the
ﬁndings in patient-derived cells. Importantly, E2 treatment did
not affect the levels of G6PD protein in TSC2-re-expressing
patient-derived (Supplementary Figure S2A) or rat-derived
cells (Supplementary Figure S2B).
Next, we examined the effect of E2 on G6PD expression in
cells lacking TSC2 in vivo. Xenograft tumors of ELT3 cells
from E2-treated mice exhibited a 3.5-fold increase of G6PD
expressionrelativetoplacebo treatment(Po0.01,Figure 4e).
Immunohistochemistry showed that G6PD accumulation was
more evident in xenograft tumors from E2-treated mice
compared with placebo-treated mice (Figure 4f). Importantly,
cells in lung metastatic lesions from E2-treated mice showed
abundant accumulation of G6PD (Figure 4f). These data
demonstrate that E2 enhances the expression of G6PD in
cells lacking TSC2 both in vitro and in vivo.
G6PD expression is estradiol dependent in female
cancers. We have found that estradiol increased the
expression of G6PD in mTORC1 hyperactive cells. To
examine the levels of G6PD in other female cancers, we
ﬁrst analyzed the frequency of genomic alterations of G6pd
from The Cancer Genome Atlas (TCGA) data set.
23 Despite
the mutation, deletion, and multiple alterations, G6pd
ampliﬁcation frequency was higher in ovary cancer (B9%),
cervix cancer (3%), uterine cancer (2%), and breast cancer
(2%) (Figure 5a). To examine the impact of E2 on the levels
of G6pd transcript in breast cancer cells, we analyzed
publicly available expression array data sets. E2 stimulation
signiﬁcantly increased the transcript levels of G6pd com-
pared with vehicle control in MCF-7 cells (GDS3217 data
set)
24 (Figure 5b). E2 starvation for 2 days signiﬁcantly
decreased the transcript levels of G6pd relative to 1-day E2
starvation or regular condition in MCF-7 cells (GDS2323 data
set)
25 (Figure 5c). Molecular depletion of ERa reduced the
transcript levels of G6pd in MCF-7 cells (GDS4061 data
set)
26 (Figure 5d). Furthermore, ER-positive breast cancer
cell line ZR75 displayed higher transcript levels of G6pd
relative to ER-negative MDA231 cell line and E2-independent
B6TC hybrid cell line (GDS4067 data set)
27 (Figure 5e).
Taken together, these data indicate that levels of G6PD are
dependent on E2 and its cognate receptor in female
predominant cancers including breast cancer cells, consis-
tent with our ﬁndings in TSC2-deﬁcient cells.
Depletion of G6PD attenuates estradiol-enhanced
survival of TSC2-deﬁcient cells in vitro and in vivo. To
determine whether inhibition of G6PD impacts the survival of
ELT3 cells in vitro, we downregulated G6PD using siRNA in
ELT3 cells, achieving B50% downregulation (Figure 6a).
G6PD knockdown prevented E2-decreased ROS production
in comparison with control siRNA (Figure 6b). Importantly,
G6PD downregulation signiﬁcantly suppressed E2-enhanced
Figure 6 Depletion of G6PD attenuatesestradiol-enhanced survival of Tsc2-deﬁcient cells in vitro and in vivo.( a) Tsc2-deﬁcient cells were transfected with control siRNA
or G6PD siRNA for 48h, and then treated with control or estradiol for 6h. Levels of G6PD, phospho-S6 (Ser235/236), and b-actin were assessed by immunoblot. The graph
indicatestheratioofG6PDtob-actin.Resultsarerepresentativeofthreedifferentexperiments.(b)Tsc2-deﬁcientcellsweretransfectedwithcontrolsiRNAorG6PDsiRNAfor
48h, and then treated with control or estradiol for 24h. Hydrogen peroxide (0.5mM) was added for 1h before measurement. Cellular ROS level was measured with the
DCFH-DA. Data were normalized to total cell number. Results are representative of eight sets of independent samples per group from three experiments.( c) Cell death was
measured using propidium iodide (PI) exclusion assay. Data were normalized to total cell number. Results are representative of eight sets of independent samples per group
from three experiments. (d) Tsc2-deﬁcient cells were treated with 6-AN (10mM) for 1h, and then treated with control or estradiol for 24h. G6PD activity was determined.
(e)Tsc2-deﬁcientcellsweretreatedwith6-AN(10mM)for1h,andthentreatedwithcontrolorestradiol(10nM)for2and24h.CellularNADPHlevelwasmeasured.Datawere
normalized to total protein level. Results are representative of three sets of independent samples per group from three experiments. (f) Tsc2-deﬁcient cells were treated with
6-AN (10mM) for 1h, and then treated with control or estradiol (10nM) for 24h. Cellular ROS level was measured with the DCFH-DA. Data were normalized to cell number.
Results are representative of eight sets of independent samples per group from three experiments. (g) Tsc2-deﬁcient cells were treated with 6-AN (10mM) for 1h, and then
treated with control or estradiol (10nM) for 24h. Cell death was measured using the PI exclusion assay. Data were normalized to cell number. Results are representative of
eightsetsofindependentsamplespergroupfromthreeexperiments.(h)FemaleCB17SCIDmiceweresupplementedwithestradiolfor1week,andthentreatedwith6-ANor
vehicle for 2 days. ELT3-luciferase cells were treated with 6-AN for 18h, and then injected intravenously into mice (n¼5/group). Lung colonization was measured using
bioluminescence at 0.5, 6, and 24h after injection. Representative images are shown. Total photon ﬂux/second present in the chest regions in estradiol (n¼5) and estradiol
plus 6-AN-treated (n¼5) animals. (i) Scheme of estradiol-promoted pentose phosphate pathway addiction in TSC2-deﬁcient cells. *Po0.05, **Po0.01
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Cell Death and Diseasesurvival of Tsc2-deﬁcient ELT3 cells after H2O2 treatment
(Figure 6c).
To inhibit G6PD pharmacologically, we treated Tsc2-
deﬁcient cells with 6-AN, an inhibitor of G6PD and pentose
phosphate pathway. 6-AN treatment signiﬁcantly decreased
E2-induced G6PD activity (Po0.01, Figure 6d), E2-enhanced
cellular level of NADPH (Po0.01, Figure 6e), and E2-reduced
ROS production (Po0.05, Figure 6f). Importantly, 6-AN
treatment signiﬁcantly suppressed E2-enhanced survival
of ELT3 cells after H2O2 treatment (Po0.05, Figure 6g).
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Cell Death and DiseaseThese data indicate that depletion of G6PD attenuates
E2-enhanced survival of ELT3 cells in vitro.
To investigate further the role of G6PD on the survival of
ELT3 cells in vivo, ELT3 luciferase cells
28 were intravenously
injected into mice treated with E2 alone or E2 plus 6-AN. At 0.5
and 6h post cell inoculation, similar levels of bioluminescence
were observed in the chest regions of all mice. At 24h, the
bioluminescence in the chest regions of the E2 plus
6-AN-treated mice was decreased by B80% as compared
with that in the E2-treated mice (Po0.05, Figure 6h). These
data support a model in which inhibition of G6PD attenuates
E2-enhanced survival of Tsc2-deﬁcient cells in vivo.
Discussion
LAM is a female predominant lung disease characterized by
the abnormal proliferation of smooth muscle cells and
progressive cyst formation that can lead to respiratory
failure.
1–3 The gender speciﬁcity of LAM suggests that
estradiol may contribute to disease progression, whereas
mTORC1, which is hyperactive in LAM cells, is a master
regulator of cellular metabolism. However, the role of estradiol
in regulating the metabolism in Tsc2-deﬁcient cells has not
been extensively investigated. In this study, we identiﬁed an
estradiol-enhanced glucose and pentose phosphate pathway
signature in Tsc2-deﬁcient rat uterine leiomyoma-derived
ELT3 cells in vitro. Estradiol treatment led to increasedcellular
NADPHanddecreasedROSandenhancedcellsurvivalunder
oxidative stress. Estradiol also induced plasma membrane
translocation of GLUT1 or GLUT4 and increased glucose
uptake in a PI3K/Akt-dependent manner.
18F-FDG-PET/CT
imaging showed enhanced glucose uptake in xenograft
tumors from estradiol-treated mice. Depletion of G6PD, a
rate-limiting enzyme for the pentose phosphate pathway,
suppressedestradiol-enhancedsurvivalofTsc2-deﬁcientcells
in vitro and in vivo. Collectively, these data indicate that
estradiol promotes glucose metabolism through the pentose
phosphatepathway in cellswithmTORC1hyperactivation and
enhances cell survival under oxidative stress.
Alterations in cellular energy metabolism are a hallmark of
cancer,
6 and there are many indications that metabolic
reprogramming is particularly critical for the survival of
Tsc2-deﬁcient cells. Glucose addiction of Tsc2-deﬁcient cells
has been reported,
8 suggesting that glucose metabolism is
essential for the survival of Tsc2-deﬁcient cells. TSC2 deﬁciency
leads to increased transcript levels of glucose metabolism
genes.
10 Cells with mTORC1 activation express high levels of
glycolytic proteins PKM2.
11 Somewhat surprisingly, however,
the mTORC1 inhibitor rapamycin reduces lactate production but
does not affect cellular ATP levels in Tsc2
 /  MEF cells.
9
Together, these reports highlight connections between cellular
metabolic alterations and glucose utilization that is likely to
impact TSC2-deﬁcient LAM cells.
18F-FDG-PET scanning has been performed in LAM
patients. One case report described a strong FDG uptake in
pulmonary LAM.
29 Moreover, Young et al.
30 performed
FDG-PET scanning in 12 LAM patients and FDG-PET was
negative for all patients. Reasons for the negativity of
FDG-PET in LAM patients may include: (1) the sensitivity of
PET detection because of the diffused inﬁltration of LAM
cells; (2) emphysema-like destruction of lung parenchyma;
1
(3) downregulation and cytoplasmic localization of glucose
transporters in cells lacking TSC2;
31 (4) glucose uptake and
PET positivity may be cyclical, depending on circulating
estrogen levels.
We previously showed that estradiol promotes the metastasis
of Tsc2-deﬁcient ELT3 tumors in a MEK1/2-dependent
manner.
28 Here, we report that estradiol promotes glucose
metabolism via the pentose phosphate pathway in TSC2-
deﬁcient cells, associated with a MEK1/2-independent but PI3K/
Akt-dependent plasma membrane translocation of GLUT1 or
GLUT4. This is particularly interesting, because it has been
previouslydemonstratedthatGlut1andGlut4arelocalizedinthe
cytoplasm but not in the plasma membrane in Tsc2-deﬁcient
cells,
31 which may limit their ability to proliferate especially under
conditions of bioenergetic stress. Our ﬁnding that estradiol is
sufﬁcient to restore membrane localization of the GLUT1 or
GLUT4transporterandenhanceglucoseuptakemay,therefore,
represent a key pathogenic mechanism underlying the female
predominance of LAM (Figure 6i).
LAMcanleadtorespiratoryfailureanddeath.
1–3Therecent
MILES trial demonstrated that the mTORC1 inhibitor
Sirolimus stabilizes lung function in women with LAM.
However, lung function decline resumed upon drug
discontinuation.
32 Therefore, despite many advances in the
clinical care of women with LAM, there remains a critical need
for improved therapeutic options. The fact that estradiol
promotes glucose utilization and cell survival via the pentose
phosphate pathway suggests that inhibiting the PPP could
selectively inhibit estrogen-induced cell survival. Consistent
with this hypothesis, we found that 6-AN blocked estrogen-
induced survival both in vivo and in vitro, suggesting a
novel therapeutic approach for LAM. Our data suggest that
inhibiting estrogen-dependent cellular metabolic pathways
could block the pro-survival effects of estrogen on LAM cells,
without the need to ablate the entire hormonal signaling axis.
In the long term, it is possible that metabolically focused
strategies in LAM could have preferable side effect proﬁles
compared with hormonal ablation in terms of bone health and
other parameters; clearly additional pre-clinical and clinical
studies will be needed to test this concept.
Materials and Methods
Cell line and culture. Eker rat uterine leiomyoma-derived cells (ELT3),
14,15
ELT3 luciferase-expressing cells,
28 and LAM patient-derived cells (developed from
a sporadic LAM-associated renal angiomyolipoma cells carrying biallelic mutations
of the TSC2 gene
33) were cultured in IIA complete medium supplemented with
10% FBS. Prior to estradiol stimulation, cells were starved in serum-free and
phenol red-free IIA media for 24h.
Antibodies and chemicals. The following chemicals were used: 17-beta-
estradiol, wortmannin and DAPI (Sigma-Aldrich, St. Louis, MO, USA), rapamycin
(L C Laboratories, Woburn, MA, USA), PD98059 (Cell Signaling Technologies,
Danvers, MA, USA), MK2206 (Active Biochem, Maplewood, NJ, USA), and
AZD6244 (L C Laboratories). Antibodies included phospho-ERK1/2 (T202/Y204),
phospho-S6 (S235/236), phospho-Akt (S473) and TSC2 (Cell Signaling
Technologies), G6PD and GLUT1 (H-43) (Santa Cruz Biotechnology, Dallas,
TX, USA), GLUT4 and b-actin (Sigma-Aldrich), and Alexa Fluor 488 Goat Anti-
Rabbit IgG (Invitrogen, Grand Island, NY, USA).
Metabolomic proﬁling. Cell pellets were submitted to Metabolon Inc.
(Durham, NC, USA) for sample extraction and analysis. Brieﬂy, Metabolon
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Cell Death and Diseaseperformed cold methanol extraction of cell pellets and these extracts were split into
three aliquots. These aliquots were processed and characterized by one of the
three analytical methods previously described.
34,35
Cellular NADPH quantiﬁcation. Cells were seeded in 12-well plates,
treated with siRNA or inhibitors, and then stimulated with control or estradiol
(10nM). Cells (1 10
5) were harvested and lysates were extracted with 200mlo f
extraction buffer following the manufacture’s instruction. Levels of NADPH were
measured using the NADP/NADPH Assay kit (Abcam, Cambridge, MA, USA) and
normalized to total cellular proteins.
Quantiﬁcation of ROS. Cells were seeded in 96-well plates and incubated
with 50mM DCFH-DA in 1 -DPBS for 45min at 371C. Fluorescence was read at
485nm/525nm. Levels of cellular ROS were normalized to the total number
of cells.
Measurement of cell survival. Cells were plated in 96-well plates,
incubated with propidium iodide (5mM) in 100ml1 -DPBS for 30min at 371C.
Fluorescence was read at 530nm/620nm. Data were represented as percentage
of dead cells relative to the total number of cells. Cell growth was measured using
crystal violet assay.
Immunoblotting. Cells were lysed in M-PER buffer (Pierce, Rockford, IL,
USA) supplemented with protease inhibitors and phosphatase inhibitor cocktails.
Cleared cell lysates were obtained by centrifugation at 14000r.p.m. for 10min at
41C and then subjected to immunoblotting.
Animal studies. All animal work was performed in accordance with
protocols approved by the Institutional Animal Care and Use Committee-
Children Hospital Boston. For xenograft tumor establishment, 1 week
before cell inoculation, mice were implanted with estradiol pellets (90-day
release, 2.5mg/pellet, Innovative Research of America, Sarasota, FL, USA) or
placebo pellets. Two million ELT3 cells were inoculated bilaterally into the
posterior back region of the mice. Mice bearing subcutaneous tumors
(B250mm
3) underwent FDG-PET scanning. For the intravenous model, 0.5
million ELT3 luciferase cells in a volume of 100ml were injected intravenously
into the tail vein of the CB-17 SCID mice pretreated with estradiol (500nM in
drinking water) for 2 days before cell injection.
Immunohistochemistry. Sections were deparafﬁnized, incubated with
primary antibodies and biotinylated secondary antibodies, and counterstained
with Gill’s Hematoxylin.
Immunoﬂuorescence. Cells were plated on glass coverslips, serum starved
overnight, treated with rapamycin (10nM) or wortmannin (500nM) for 15min, and
then stimulated with control or estradiol (10nM) for 12 or 24h. Cells were ﬁxed
with 50% methanol plus 50% acetone for 2min, blocked in 1% BSA/PBS/Tween
20 (0.05%) for 30min, incubated with primary antibody for 1h and then secondary
antibodies for 1h. Images were captured with a FluoView FV-10i Olympus Laser
Point Scanning Confocal Microscope, Olympus (Center Valley, PA, USA).
2-NBDG uptake. 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglu-
cose (2-NBDG, Cayman Chemical, Ann Arbor, MI, USA), a glucose analog
ﬂuorescently labeled at the two position, is a substrate for glucose transporters.
36
Cells were cultured in IIA medium with 10% FBS, starved with serum-free and
phenol-free IIA medium overnight, pretreated with inhibitors for 15min, and then
stimulated with E2 (10nM) for 24h. Medium was changed to phenol-free serum-
free glucose-free DMEM with 50mmol/l 2-NBDG for 30min. Internalization of
2-NBDG was monitored using confocal microscopy. 2-NBDG uptake was
quantiﬁed using ﬂuorescence intensity and normalized to control.
Glucose assay. Cells were seeded in 12-well plates, treated with inhibitors,
and then stimulated with control or estradiol (10nM). Conditioned media was
collected and subjected to glucose quantiﬁcation using the Glucose (HK) Assay Kit
(Sigma-Aldrich).
18F-FDG-PET imaging. Mice bearing subcutaneous tumors (B250mm
3)
were intravenously injected with 150mCi of [
18F]FDG. After 30min, animals were
anesthetized with 2% isoﬂuorane, and imaged for 15min using a small animal
PET/CT scanner (eXplore Vista, GE Healthcare, Waukesha, WI, USA). Images
were reconstructed using Fourier rebinning (FORE) and ordered subsets
expectation maximization algorithm with 16 subsets and 2 iterations. The voxel
dimensions of the reconstructed images were 0.39 0.39 0.78mm
3.[
18F]FDG
uptake in each mouse normalized to the body weight and injected FDG dose, and
was presented as SUV.
TCGA data analysis. Genomic alterations of G6pd data for all TCGA cases
were analyzed from TCGA data sets obtained from the cBioPortal for Cancer
Genomics (http://www.cbioportal.org/public-portal/index.do).
Gene expression analysis. The publicly available microarray GEO data
sets (www.ncbi.nlm.nih.gov/geo/) were collected. The Z-score of G6pd mRNA was
used for data analysis.
siRNA transfection. Control-siRNA (50nM) or G6PD-siRNA (Dharmacon,
Pittsburgh, PA, USA) were transfected in cells using TransIT-TKO reagent
(Mirus, Madison, WI, USA). Cells were harvested at 48–60h post transfection.
G6PD activity assay. Cells were seeded in 12-well plates, treated with
inhibitors, and then stimulated with control or estradiol (10nM). Cells (1 10
5)
were collected and lysates were extracted with 200ml of extraction buffer following
the manufacture’s protocol. G6PD activity was quantiﬁed using G6PD Activity
Colorimetric Assay kit (Biovision, Milpitas, CA, USA). G6PD activity was
normalized to total protein levels.
Bioluminescent reporter imaging. Ten minutes before imaging, animals
were injected with luciferin (Xenogen, Waltham, MA, USA) (120mg/kg, i.p.).
Bioluminescent signals were recorded using the Xenogen IVIS System. Total
photon ﬂux of the chest area was analyzed.
28
Statistical analyses. All data are shown as mean±S.E.M. Measurements
at single time points were analyzed by ANOVA and, if they demonstrated
signiﬁcance, were further analyzed by a two-tailed t-test. All statistical tests were
conducted using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA).
Po0.05 was used to deﬁne statistical signiﬁcance.
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